BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
Top Page
BriaCell Therapeutics
(TSX:BCT)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$6.00
▼(-43.61% Downside)
Action:ReiteratedDate:03/12/26
The score is driven primarily by weak financial performance: no revenue, widening losses, and substantial cash burn that increases funding risk. Technicals add modest pressure given the stock remains below key longer-term moving averages with negative MACD, while valuation offers limited support due to negative earnings and no indicated dividend.
Positive Factors
Balance sheet strength (no debt)
Zero reported total debt and an equity position that recovered from negative to positive in 2025 and TTM materially lower structural leverage risk. This durable financial footing improves solvency resilience, preserves strategic optionality for R&D funding, and reduces near-term default/refinancing pressure.
Negative Factors
No revenue / negative gross profit
The absence of revenue and persistent negative gross profit is a structural constraint for a sustainable business model. Without commercial revenues, the company must rely on external capital to fund R&D, leaving long-term viability tied to clinical success and future fundraising rather than internally generated cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength (no debt)
Zero reported total debt and an equity position that recovered from negative to positive in 2025 and TTM materially lower structural leverage risk. This durable financial footing improves solvency resilience, preserves strategic optionality for R&D funding, and reduces near-term default/refinancing pressure.
Read all positive factors
BriaCell Therapeutics (BCT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$39.01M
Dividend YieldN/A
Average Volume (3M)3.11K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth62.01%
CountryCA
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.58
Shares Outstanding7,250,487
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BriaCell Therapeutics Business Overview & Revenue Model
Company Description
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical tri...
How the Company Makes Money
null...
BriaCell Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -110.60K | -147.89K | -114.04K | -20.49K | -19.39K | -19.44K |
| EBITDA | -39.27M | -36.63M | -45.91K | -27.23M | -34.05M | -6.95M |
| Net Income | -45.80M | -36.50M | -6.62K | -20.30M | -11.58M | -2.90M |
Balance Sheet | ||||||
| Total Assets | 45.49M | 21.65M | 5.87M | 27.16M | 42.58M | 58.04M |
| Cash, Cash Equivalents and Short-Term Investments | 40.49M | 17.87M | 862.09K | 21.25M | 41.04M | 57.27M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.99K |
| Total Liabilities | 4.58M | 4.32M | 8.56M | 30.94M | 32.25M | 782.24K |
| Stockholders Equity | 41.87M | 24.72M | -2.38M | -3.78M | 10.33M | 57.26M |
Cash Flow | ||||||
| Free Cash Flow | -37.04M | -28.17M | -24.58M | -23.74M | -12.48M | -7.75M |
| Operating Cash Flow | -37.04M | -28.17M | -24.13M | -23.74M | -12.48M | -7.75M |
| Investing Cash Flow | 2.50M | -7.65M | -681.80K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 66.94M | 45.45M | 4.42M | 3.95M | -3.74M | 65.00M |
BriaCell Therapeutics Technical Analysis
Negative
10.64
Price Trends
5.72
Negative
9.27
Negative
14.35
Negative
Market Momentum
-0.10
Negative
43.36
Neutral
5.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BCT, the sentiment is Negative. The current price of 10.64 is above the 20-day moving average (MA) of 5.62, above the 50-day MA of 5.72, and below the 200-day MA of 14.35, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 43.36 is Neutral, neither overbought nor oversold. The STOCH value of 5.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BCT.
BriaCell Therapeutics Risk Analysis
BriaCell Therapeutics disclosed 50 risk factors in its most recent earnings report. BriaCell Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BriaCell Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BCT
BriaCell Therapeutics
5.38
-52.72
-90.74%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.09
-43.59%
TSE:MBX
Microbix Biosystms
0.24
-0.20
-45.98%
TSE:RVX
Resverlogix
0.12
0.08
187.50%
TSE:GSD
Devonian Health Group
11.50
-3.50
-23.33%
TSE:TTI
Thiogenesis Therapeutics Corp
0.46
-0.20
-30.30%
BriaCell Therapeutics Corporate Events
Business Operations and StrategyShareholder Meetings
BriaCell Shareholders Overwhelmingly Back Board and Auditors at Annual Meeting
Positive
Mar 5, 2026
BriaCell Therapeutics reported that 48.31% of its outstanding common shares were represented at its annual general and special meeting for the year ended July 31, 2025, held on March 5, 2026. Shareholders overwhelmingly approved all resolutions, i...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
BriaPro to Acquire BriaCell’s Soluble CD80 License in Strategic Cancer Immunotherapy Deal
Positive
Feb 18, 2026
BriaCell Therapeutics and its majority-owned subsidiary BriaPro Therapeutics have signed a definitive asset purchase agreement under which BriaPro will acquire BriaCell’s exclusive license to develop and commercialize the Soluble CD80 biolog...
Business Operations and Strategy
BriaCell Wins Fifth Straight Safety Nod for Fast-Track Phase 3 Breast Cancer Trial
Positive
Feb 17, 2026
BriaCell Therapeutics has received a fifth consecutive positive recommendation from an independent Data Safety Monitoring Board for its pivotal Phase 3 Bria-ABC study evaluating Bria-IMT in combination with an immune checkpoint inhibitor in metast...
Business Operations and Strategy
BriaCell Imaging Data Show Tumor Regression and Immune Activation in Metastatic Breast Cancer Trial
Positive
Jan 28, 2026
BriaCell Therapeutics has released new imaging data from its Phase 2 study of Bria-IMT in heavily pre-treated metastatic breast cancer patients, showing regression and resolution of metastatic lesions in the eye orbit, temporal lobe of the brain, ...
Business Operations and Strategy
BriaCell Reports Prolonged Survival in Phase 2 Metastatic Breast Cancer Trial
Positive
Jan 27, 2026
BriaCell Therapeutics reported updated Phase 2 data for its Bria-IMT immunotherapy regimen in metastatic breast cancer, showing that 9 of 25 patients treated since 2022 remain alive more than 18 to 47 months after enrollment, markedly exceeding su...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
BriaCell Raises $30 Million Through Public Offering of Units and Listed Warrants
Positive
Jan 14, 2026
BriaCell Therapeutics has priced a best-efforts public offering of 5,366,726 units, each comprising one common share or pre-funded warrant and one warrant, at $5.59 per unit for expected gross proceeds of approximately $30 million before fees and ...
Business Operations and StrategyProduct-Related Announcements
BriaCell Reports Year-Long Complete Lung Metastasis Response in Breast Cancer Trial
Positive
Jan 13, 2026
BriaCell Therapeutics reported an 11‑month sustained complete resolution of a lung metastasis in a 78‑year‑old patient with hormone receptor–positive, HER2‑negative metastatic breast cancer treated with its personaliz...
Business Operations and StrategyProduct-Related Announcements
BriaCell’s Phase 3 Breast Cancer Trial Named a 2026 ‘Clinical Trial to Watch’ by Nature Medicine
Positive
Dec 18, 2025
BriaCell Therapeutics’ pivotal Phase 3 trial of its lead immunotherapy candidate Bria-IMT in metastatic breast cancer has been highlighted by Nature Medicine as one of the “clinical trials to watch in 2026,” underscoring rising s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.